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aapid and accurate risk stratification of acute pulmonary
mbolism (PE) has focused on the anatomic size of the
hrombus as well as the PE’s physiological effects on
ystemic arterial pressure, heart rate, and chest computed
omographic or echocardiographic evidence of right ventric-
lar enlargement or dysfunction. Pulmonary embolism can
lso unleash a myriad of detrimental biochemical conse-
uences. For example, release of neurohumoral factors such
s serotonin can explain, at least in part, the pulmonary
rterial hypertensive response to PE. The same cardiac
iomarkers used to assess heart damage due to acute
yocardial infarction can be used to help prognosticate after
he diagnosis of acute PE is established. To quantify
icronecrosis and microinfarction of the right ventricle,
ssay of troponin levels is part of the standard workup (1).
e can also quantify right ventricular myocardial stretch
ue to right ventricular overload by relying on 2 additional
ardiac biomarkers—brain natriuretic peptide (BNP) (2)
nd pro-BNP (3)—even though their utility in clinical
ecision-making for PE management remains uncertain.
See page 2150
Fatty acid binding proteins are small cytoplasmic proteins
hat reversibly bind hydrophobic ligands such as saturated
nd unsaturated long chain fatty acids, eicosanoids, and
ther lipids (4). Fatty acid binding proteins help maintain
embrane integrity by protecting the cell from the deter-
ent effects of excess nonprotein-bound fatty acids. They
lso facilitate transport of fatty acids and other lipid medi-
tors throughout the cytoplasm of the cell.
Heart-type fatty acid binding proteins (hFABPs) are a
ensitive biomarker of myocardial necrosis. After myocardial
schemic damage, hFABPs are released from damaged
yocytes within 1 to 3 h and return to normal within 12 to
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ifferent enzyme-linked immunoadsorbent assay kits, but
one have been approved for clinical diagnostic use. How-
ver, a commercially available point-of-care test (6) for
hole blood samples (Rennesens, Berlin, Germany) (7) has
een approved for diagnosis of myocardial infarction in
urope and in approximately 20 non-European countries
ut not in the U.S. In a registry of 2,287 acute coronary
yndrome patients, hFABP elevation was independently
ssociated with an increased risk of death, heart failure, and
ecurrent ischemic events (8). In a subsequent registry of
,448 patients with acute coronary syndrome, elevated
FABP levels predicted long-term mortality and identified
igh-risk patients in a manner additive to clinical risk
actors, troponin, and C-reactive protein. The purported
echanism to explain the advantage of hFABP is that
etectable hFABP is released faster than troponin. In
ddition, hFABP might be released after myocardial isch-
mia with or without necrosis (9), whereas troponin is
eleased only after necrosis.
Puls et al. (10) studied hFABP in 107 consecutive
atients with acute PE. Abnormally elevated (i.e., 6
g/ml) plasma levels of hFABP on admission were very
eliable predictors of adverse outcome. Their prognostic
alue seemed superior to that of troponin and proBNP.
here was almost no overlap between patients who subse-
uently suffered major complications and those with an
ncomplicated course with regard to baseline hFABP con-
entrations. No patients with initially normal hFABP levels
ad a complicated 30-day outcome or died of PE-related
auses. With respect to death or major PE-related compli-
ations, the positive predictive value (41%) of hFABP was
uperior to that of troponin (29%) and proBNP (19%). The
FABP but not troponin or proBNP remained a highly
ignificant predictor of adverse outcome when the 3 biomar-
ers were compared with multivariable analysis. Moreover,
nalysis of hFABP in combination with echocardiography
evealed that cardiac ultrasound offered no incremental
rognostic information in the presence of a normal hFABP
est. By contrast, in patients with hFABP 6 ng/ml on
dmission (27% of the entire study population), complica-
ion rates doubled, and the relative risk of an adverse
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entricular dysfunction on echocardiography.
In this issue of the Journal, the Konstantinides Labora-
ory has made an important contribution to our knowledge
bout cardiac biomarker use in normotensive patients with
ewly diagnosed acute PE (11). They studied 126 consec-
tive normotensive acute PE patients, of whom 7% suffered
eath, resuscitation, intubation, or use of catecholamines
ithin 30 days. An elevated hFABP level was associated
ith an independent 16-fold increased likelihood of death
r major complication within 30 days. The hFABP was also
strong predictor of long-term mortality. Most striking are
he 2 figures in this report. The first figure provides receiver
perating characteristic curves for hFABP, troponin, and
roBNP levels. The hFABP was far more sensitive and
pecific for predicting 30-day complications than the other
ardiac biomarkers. Qualitatively, this is depicted with a
uch higher “left shoulder” on the receiver operating
haracteristic curve than troponin or proBNP. The second
gure shows that an elevated hFABP level is a much more
owerful predictor of reduced long-term survival than ele-
ation in troponin or pro-BNP.
These findings about the clinical utility of hFABP for
cute PE risk stratification are welcome news. Too often,
levated troponin levels have served as “false alarms,” with
atients subjected to prolonged hospital stay and triage to
ntensive Care Unit beds on the basis of a “troponin leak.”
f course, no biomarker should be used outside of the
linical context for which it is developed. In the case of acute
E, no biomarker testing at all is required if the patient
resents with massive PE, especially accompanied by sys-
emic arterial hypotension requiring pressor support. At the
ther end of the spectrum, a PE patient who seems clinically
table, with a normal heart rate, blood pressure, and
espiratory rate, as well as normal oxygen saturation and
ormal right ventricular size on chest computed tomogra-
hy scan, will have an excellent prognosis. Cardiac biomar-
er testing in this context might be “icing on the cake.”
owever, even though the cost of biomarker testing is
odest, we might not be able to afford this luxury routinely
f we wish to maximize the impact of each health care dollar
hat we spend.
For now, I think that hFABP testing should be paired
ith troponin so that we can create a larger database to
etermine the day-to-day clinical utility of the hFABP
iomarker in acute PE management. Reports on only
everal hundred PE patients have been published. We can
ssume that the enzyme-linked immunoadsorbent assay,
hich was used in the current study and which provides
recise quantitative results, will be a more useful test than
he qualitative point-of-care device that is widely available
n Europe. Another unresolved issue is how the time course
f PE will affect the hFABP result. In acute myocardial
K
pnfarction, hFABP returns to normal within 24 h. Will a
arger sample of acute PE patients, who are often not
iagnosed until 5 days or longer after the onset of symp-
oms, reveal that high-risk patients with late presentation
ave normal hFABP levels? Finally, we must ask whether
FABP will compare favorably to the new generation of
igh-sensitivity troponin assays (12).
The present study opens the door to possibly more precise
rognostication in patients with acute PE. The authors
howed that the combination of elevated hFABP and
achycardia was especially ominous. As clinical research
ntensifies for PE risk stratification, hFABP seems to be a
elcome addition to our armamentarium of clinical assess-
ent, imaging, and biomarker evaluation.
eprint requests and correspondence:Dr. Samuel Z. Goldhaber,
righam and Women’s Hospital, Cardiovascular Division, De-
artment of Medicine, 75 Francis Street, Boston, Massachusetts
2115-6110. E-mail: sgoldhaber@partners.org.
EFERENCES
1. Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins
in acute pulmonary embolism: a meta-analysis. Circulation 2007;116:
427–33.
2. Kucher N, Printzen G, Doernhoefer T, Windecker S, Meier B, Hess
OM. Low pro-brain natriuretic peptide levels predict benign clinical
outcome in acute pulmonary embolism. Circulation 2003;107:1576–8.
3. Kostrubiec M, Pruszczyk P, Kaczynska A, Kucher N. Persistent
NT-proBNP elevation in acute pulmonary embolism predicts early
death. Clin Chim Acta 2007;382:124–8.
4. Makowski L, Hotamisligil GS. Fatty acid binding proteins—the
evolutionary crossroads of inflammatory and metabolic responses.
J Nutr 2004;134:2464S–8S.
5. Kleine AH, Glatz JF, Van Nieuwenhoven FA, Van der Vusse GJ.
Release of heart fatty acid-binding protein into plasma after acute
myocardial infarction in man. Mol Cell Biochem 1992;116:155–62.
6. Mad P, Domanovits H, Fazelnia C, et al. Human heart-type fatty-
acid-binding protein as a point-of-care test in the early diagnosis of
acute myocardial infarction. QJM 2007;100:203–10.
7. Watanabe T, Ohkubo Y, Matsuoka H, et al. Development of a simple
whole blood panel test for detection of human heart-type fatty
acid-binding protein. Clin Biochem 2001;34:257–63.
8. O’Donoghue M, de Lemos JA, Morrow DA, et al. Prognostic utility
of heart-type fatty acid binding protein in patients with acute coronary
syndromes. Circulation 2006;114:550–7.
9. Kilcullen N, Viswanathan K, Das R, et al. Heart-type fatty acid-
binding protein predicts long-term mortality after acute coronary
syndrome and identifies high-risk patients across the range of troponin
values. J Am Coll Cardiol 2007;50:2061–7.
0. Puls M, Dellas C, Lankeit M, et al. Heart-type fatty acid-binding
protein permits early risk stratification of pulmonary embolism. Eur
Heart J 2007;28:224–9.
1. Dellas C, Puls M, Lankeit M, et al. Elevated heart-type fatty
acid-binding protein levels on admission predict an adverse outcome in
normotensive patients with acute pulmonary embolism. J Am Coll
Cardiol 2010;55:2150–7.
2. Hollander JE. Highly sensitive troponins: the answer or just more
questions? J Am Coll Cardiol 2009;54:1173–5.ey Words: biomarkers y heart-type fatty acid-binding protein y
rognosis y pulmonary embolism y risk stratification.
